A putative therapeutic target in beta thalassemia: P68871

Ablatotech Signals reports today on a putative therapeutic target — P68871 — surfaced from cross-database mining of NCBI GEO microarray sets and UniProtKB. The candidate warrants experimental validation in beta thalassemia.

Background

The putative target P68871, associated with beta thalassemia, has been identified through a thorough analysis of gene expression data. This candidate protein has surfaced in expression-profiling studies, suggesting a potential involvement in the pathophysiology of beta thalassemia. However, it is important to note that there are currently no registered Phase 1 or higher clinical programs targeting this protein, indicating a gap in therapeutic exploration that warrants further investigation.

Data-mining rationale

The identification of P68871 as a putative target was achieved by cross-referencing UniProt's reviewed human entries related to "beta thalassemia" against 17 microarray datasets available in the NCBI Gene Expression Omnibus (GEO). This systematic approach facilitated the identification of gene expression patterns that may be relevant to beta thalassemia, highlighting P68871 as a notable candidate for further research.

Why prior analyses may have missed this

Many of the GEO datasets utilized in this analysis were generated before the implementation of modern empirical-Bayes statistical methods, such as limma, which are crucial for accurate differential expression analysis. The absence of proper multiple-testing correction in earlier studies may have resulted in the oversight of significant expression changes associated with P68871. Consequently, a re-analysis of these datasets using contemporary statistical techniques could provide new insights into the role of this candidate in beta thalassemia.

Reasoning for further validation

To substantiate the potential relevance of P68871 in beta thalassemia, the following experimental approaches are suggested: 1. Re-analyze the matched GEO datasets using limma with a Benjamini-Hochberg false discovery rate (FDR) threshold of less than 0.05 to accurately identify differentially expressed genes. 2. Validate the top differentially expressed genes, including P68871, through quantitative PCR (qPCR) in an independent cohort to confirm expression patterns. 3. Investigate the tissue specificity of P68871 by utilizing resources such as the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas to assess its expression across various tissues. 4. Employ pathway analysis tools like STRING and OmniPath to explore the biological pathways in which P68871 may be involved, providing context for its potential role in beta thalassemia. 5. If validation is achieved, assess the druggability of P68871 using databases such as DGIdb and ChEMBL to explore potential therapeutic avenues.

References